Where Tech Meets Bio

Where Tech Meets Bio

Home
Weekly Highlights
Deep Dives
Sponsored Features
About

December 2025

Weekly Tech+Bio Highlights #67: Wrapping Up 2025
First-wave AI drug builder steps back from the clinic, platform-native developer heads for IPO, a model-discovered drug enters Phase 1, & pharma…
 • Roman Kasianov and BiopharmaTrend
Weekly Tech+Bio Highlights #66: AI Antibody Startup Hits Unicorn Status
Merck & Nvidia Debut Open-Source Drug Model; Microsoft’s Spatial Proteomics, & First Non-Profit Gets FDA Approval for Gene Therapy
 • Roman Kasianov and BiopharmaTrend
Aging, AI, and the Uneven Road to Longevity Medicine
Echoing notes from ARDD2025, we briefly overview geroscience, its fusion with AI, what companies pursue in this field and limitations on the way of…
 • BiopharmaTrend
Weekly Tech+Bio Highlights #65: Can AI Infrastructure Become Biotech’s Next Big Business?
2025 Pharma Review, Lilly Exec Explains Rationale Behind TuneLab AI Model Sharing & Biweekly News Roundup
 • Roman Kasianov and BiopharmaTrend

November 2025

Generative Diffusion in Molecular Design
A quick field guide to diffusion-based generators in molecular design—how they work, where they complement transformers, and who is deploying them today
 • BiopharmaTrend
Weekly Tech+Bio Highlights #64: Eli Lilly Reaches $1 Trillion Valuation
Merck's $3B AI drug discovery deal, new open-source virtual cell initiative, AI designing full-length antibodies, Europe’s first agentic AI…
 • BiopharmaTrend and Roman Kasianov
Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape
Drawing on new discussions from ARDD2025 in Copenhagen, the focus turns to how GLP-1s, IPF, and the gut microbiome are steering aging drug development
 • Andrii Buvailo, PhD
Weekly Tech+Bio Highlights #63: Quantum vs. AI Small Molecule Design
FDA’s pathway for custom gene editing, UK’s non-animal testing roadmap, OpenAI leads a biosecurity seed, 100x mRNA delivery & over $1B in fresh life…
 • Roman Kasianov and BiopharmaTrend
Protein Language Models: Builders & Pharma Deals
We unpack how PLMs work, notable builders, pharma deals, and current limitations
 • BiopharmaTrend
Weekly Tech+Bio Highlights #62: Virtual Biology, Open Co-Folding, and a World-Model Lab Agent
Neuralink's Rival raises $200M, AI healthcare funding at $10.7B in 2025, Lilly expands AI drug discovery via Insilico & XtalPi deals
 • Roman Kasianov and BiopharmaTrend
New LLMs, Agents, and Graphs in Life Sciences
With Claude joining the lab, we survey healthcare LLMs, their real-world use, and how neurosymbolic AI can remedy their limitations
 • BiopharmaTrend
© 2026 BiopharmaTrend (BPT Analytics Ltd) · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture